Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Industry
Pharmaceutical Preparations
Location
8000 Marina Boulevard, Suite 120, Brisbane, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.45K % +106%
Debt-to-equity 28.8 % -25.9%
Return On Equity -47.6 % +46.7%
Return On Assets -36.9 % +42.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.8M shares +23.7%
Entity Public Float 449M USD +175%
Common Stock, Value, Issued 55K USD
Weighted Average Number of Shares Outstanding, Basic 54.7M shares +23.6%
Weighted Average Number of Shares Outstanding, Diluted 54.7M shares +23.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 89.4M USD +1.97%
General and Administrative Expense 27.8M USD +14.2%
Operating Income (Loss) -117M USD -4.63%
Nonoperating Income (Expense) 9.39M USD +99.6%
Income Tax Expense (Benefit) 1K USD
Net Income (Loss) Attributable to Parent -108M USD -0.47%
Earnings Per Share, Basic -2.17 USD/shares +35.2%
Earnings Per Share, Diluted -2.17 USD/shares +35.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.1M USD -26%
Marketable Securities, Current 359M USD +144%
Other Assets, Current 429K USD -69.3%
Assets, Current 395M USD +107%
Property, Plant and Equipment, Net 155K USD +288%
Operating Lease, Right-of-Use Asset 1.93M USD -52.1%
Assets 397M USD +104%
Accounts Payable, Current 4.66M USD -64.9%
Employee-related Liabilities, Current 2.58M USD +28.9%
Accrued Liabilities, Current 11.6M USD +5.85%
Liabilities, Current 18.4M USD -31.4%
Operating Lease, Liability, Noncurrent 455K USD -82.3%
Liabilities 69.4M USD +27%
Accumulated Other Comprehensive Income (Loss), Net of Tax -450K USD -217%
Retained Earnings (Accumulated Deficit) -371M USD -41%
Stockholders' Equity Attributable to Parent 328M USD +133%
Liabilities and Equity 397M USD +104%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.8M USD -28.7%
Net Cash Provided by (Used in) Financing Activities 277M USD +156%
Net Cash Provided by (Used in) Investing Activities -219M USD -1892%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.4M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 69.1M USD -49.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.52M USD -53.3%
Deferred Tax Assets, Valuation Allowance 71.4M USD +43.8%
Deferred Tax Assets, Gross 72.1M USD +42.1%
Operating Lease, Liability 2.57M USD -49.9%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 3.37M USD -47.4%
Operating Lease, Liability, Current 2.12M USD -17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.88M USD -37.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 802K USD -37.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 27.5M USD +25.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.51M USD +60.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 764K USD +2.41%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 719K USD -33.8%
Share-based Payment Arrangement, Expense 15.1M USD +43.5%
Interest Expense 5.82M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%